Enterprise Value
4.742M
Cash
51.54M
Avg Qtr Burn
-3.299M
Short % of Float
1.52%
Insider Ownership
23.35%
Institutional Own.
27.29%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LP-100 (Irofulven) Details Cancer, Castration-resistant prostate cancer | Phase 2 Data readout | |
LP-300 Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout |